# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA2349996 | B | Ratio of Kinact to Ki for inhibition of human KAT2 | Homo sapiens | 10 | single protein format | Scientific Literature | ||
2. | ALA2349997 | B | Inhibition of human KAT2 using L-kynurenine as substrate measured every 5 mins for 16 hours by UV-visible spectra analysis | Homo sapiens | 10 | single protein format | Scientific Literature | ||
3. | ALA2349998 | B | Inhibition of human KAT2 using L-kynurenine as substrate after 15 to 20 hrs by UV-visible spectra analysis | Homo sapiens | 10 | single protein format | Scientific Literature | ||
4. | ALA3705555 | B | Inhibition Spectra Assay : Formation of kynurenic acid (KYNA) is indirectly assessed by a decrease in light absorbance at 370 nm (OD370) as the L-kynurenine (KYN) substrate is converted by the human KAT II (hKAT II) enzyme into KYNA. | Homo sapiens | 29 | single protein format | BindingDB Database | ||
5. | ALA3706077 | B | Inhibition Spectra Assay: Formation of kynurenic acid (KYNA) is indirectly assessed by a decrease in light absorbance at 370 nm (OD370) as the L-kynurenine (KYN) substrate is converted by the human KAT II (hKAT II) enzyme into KYNA. An inhibitor would therefore inhibit the decrease in OD370.The protocol was performed by placing the following reagents into a Costar 384 well black plate (30 uL total assay volume/well): 10 uL of 3x concentrated compound; 10 uL of 3x concentrated substrate mix (BGG (Sigma G-5009); 3 mM L-Kynurenine in 150 mM Tris Acetate (Sigma K3750); 3 mM alpha-ketoglutaric acid in 150 mM Tris Acetate (Sigma K2010); and 210 uM pyridoxal 5-phosphate (PLP) in 150 mM Tris Acetate (Sigma 9255)); and 10 uL of 3x concentrated enzyme (15 nM enzyme in 150 mM Tris Acetate with 0.3% bovine serum).Plates were sealed and incubated at 37 C. for 15-20 h before reading OD370 on a SpectraMax Plus plate reader. | Homo sapiens | 29 | single protein format | BindingDB Database |